Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials

Xiao-chen Yang; Xing-jiang Xiong; Guo-yan Yang; He-ran Wang; Jie Wang

doi:10.1007/s11655-014-1709-6

Your Location：

Home >

Browse articles >

Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials

OriginalPaper | Updated：2021-08-27

- Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials
- Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials
- 中国结合医学杂志（英文版） 2015年21卷第4期页码：312-320
- Affiliations：
  
  1. Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine,Beijing,China
  3. Cancer Research Institute, Central South University,Changsha,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-014-1709-6
  中图分类号：
- 纸质出版日期：2015，
  
  网络出版日期：2014-3-2，
Scan for full text
Yang, Xc., Xiong, Xj., Yang, Gy. et al. Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 21, 312–320 (2015). https://doi.org/10.1007/s11655-014-1709-6

Xiao-chen Yang, Xing-jiang Xiong, Guo-yan Yang, et al. Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials[J]. Chinese Journal of Integrative Medicine, 2015,21(4):312-320.
Yang, Xc., Xiong, Xj., Yang, Gy. et al. Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 21, 312–320 (2015). https://doi.org/10.1007/s11655-014-1709-6 DOI：

Xiao-chen Yang, Xing-jiang Xiong, Guo-yan Yang, et al. Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials[J]. Chinese Journal of Integrative Medicine, 2015,21(4):312-320. DOI： 10.1007/s11655-014-1709-6.

摘要

To evaluate the effectiveness and safety of Songling Xuemaikang Capsule (松龄血脉康胶囊

SXC) for the treatment of primary hypertension. An extensive search including Cochrane Library

PubMed

Cochrane Central Register of Controlled Trials (CENTRAL)

Chinese Biomedical Literature Database (CBM)

Chinese National Knowledge Infrastructure (CNKI)

Chinese Scientific Journal Database (VIP)

KoreaMed

Japanese database

and online clinical trial registry websites was performed up to February 2013. Randomized controlled trials (RCTs) regarding SXC for the treatment of primary hypertension were searched without no language restrictions. The quality of each trial was assessed according to the Cochrane Reviewers’ Handbook 5.0

and RevMan 5.0 provided by the Cochrane Collaboration. A total of 17 RCTs involving 1

778 patients were included. Meta-analysis showed that there was no significant difference between SXC and antihypertensive agents on systolic blood pressure [mean difference (MD): −0.10 [−4.83

4.63]; P=0.97] and diastolic blood pressure (MD: 1.00 [−1.16

3.16]; P=0.36)

but SXC combined with antihypertensive drugs was more effective in lowering systolic blood pressure (MD: −6.17 [−7.86

−4.49]; P<0.00001) and diastolic blood pressure (MD: −7.24 [−8.62

−5.85]; P<0.00001) compared with the antihypertensive drugs alone. SXC used alone or combined with antihypertensive drugs appear to be an effective treatment for lowering elevated blood pressure and improving symptoms in patients with primary hypertension. However

the conclusion cannot be drawn definitely due to the poor quality of the included studies. There is still an urgent need for well-designed

long-term studies to address the benefits of SXC for treating primary hypertension.

Abstract

To evaluate the effectiveness and safety of Songling Xuemaikang Capsule (松龄血脉康胶囊

SXC) for the treatment of primary hypertension. An extensive search including Cochrane Library

PubMed

Cochrane Central Register of Controlled Trials (CENTRAL)

Chinese Biomedical Literature Database (CBM)

Chinese National Knowledge Infrastructure (CNKI)

Chinese Scientific Journal Database (VIP)

KoreaMed

Japanese database

and RevMan 5.0 provided by the Cochrane Collaboration. A total of 17 RCTs involving 1

778 patients were included. Meta-analysis showed that there was no significant difference between SXC and antihypertensive agents on systolic blood pressure [mean difference (MD): −0.10 [−4.83

4.63]; P=0.97] and diastolic blood pressure (MD: 1.00 [−1.16

3.16]; P=0.36)

but SXC combined with antihypertensive drugs was more effective in lowering systolic blood pressure (MD: −6.17 [−7.86

−4.49]; P<0.00001) and diastolic blood pressure (MD: −7.24 [−8.62

the conclusion cannot be drawn definitely due to the poor quality of the included studies. There is still an urgent need for well-designed

long-term studies to address the benefits of SXC for treating primary hypertension.

关键词

Songling Xuemaikang Capsuleprimary hypertensionChinese Patent Medicinesystematic reviewrandomized controlled trials

Keywords

Songling Xuemaikang Capsuleprimary hypertensionChinese Patent Medicinesystematic reviewrandomized controlled trials

references

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–2571.

Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466–72.

Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–17.

Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002;23:177–83.

Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the New Joint National Committee guidelines: new challenges of the old problem. Arch Intern Med 2004;164:2126–2134.

Choi KM, Park HS, Han JH, Lee JS, Lee J, Ryu OH, et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006;24:1515–1521.

InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and rural Thailand—The International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Eur J Cardiovasc Prev Rehabil 2003;10:249–257.

Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. Absolute and relative risk in hypertension. In: Bulpitt CJ, ed. Handbook of hypertension. Amsterdam: Elsevier Science BV; 2000:43–57.

Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from and Italian population study. Eur Heart J 2000;21:365–370.

Ernst E, Resch KL, Mills S, Hill R, Mitchell A, Willoughby M, et al. complementary medicine—a definition. Br J Gen Pract 1995;45:506–511.

Ernst E. Complementary/alternative medicine for hypertension: mini-review. Wien Med Wochenschr 2005;155:386–391.

Huang ZG, Zhang NB. Effect of puerarin on structure and function of thoracic aorta in spontaneously hypertensive rats. Chin J Pharmacol Toxic (Chin) 2012;26:595–601.

Park G, Paudyal DP, Hwang I. Production of fermented needle extracts from red pine and their functional characterization. Biotechnol Bioproc Eng 2008;13:256–261.

Kwak CS, Moon SC, Lee MS. Antioxidant, antimutagenic, and antitumor effects of pine needles (Pinus densiflora) preview. Nutrit Cancer 2009;18:162–171.

Shono M, Shimizu I, Aoyagi E, Taniguchi T, Takenaka H, Ishikawa M, et al. Reducing effect of feeding powdered nacre of Pinctada maxima on the visceral fat of rats. Biosci Biotechnol Biochem 2008;72:2761–2763.

Xiao MF, Zhou D. Effects of “Huoxue Qianyang Granule” on renin-angiotensin system in plasma of spontaneous hypertensive rats. Shanghai J Tradit Chin Med (Chin) 2007;41:59–61.

Wan WH, Xiong WB, Zhu L. The antihypertensive effect and mechanism of Songling Xuemaikang Capsule on spontaneously hypertensive rats. Sichuan J Physiol Sci (Chin) 2005;27:133–144.

Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G. 1999 WHO/ISH hypertension guidelines—highlights & ESH update. Blood Press 2003;12:181–182.

Higgins JPT, Green S. Corchrane reviewers’ handbook 5.1.0 [updated March 2011]. Review Manager (RevMan) [Computer program]. Version 5.1.0.

Shen M. Clinical observation of Songling Xuemaikang Capsule in combination with amlodipine on patients with senile hypertension. J Pract Med (Chin) 2012;28:1711–1712.

Ge CY. Clinical observation of Songling Xuemaikang Capsule in combination with amlodipine on patients with senile hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2012;10:515–517.

Wang Q, Qiao K. The comparison of Songling Xuemaikang Capsule and nifedipine on treating primary hypertension. West China J Pharmac Sci 2006;1:107–108.

Li YD, Liu D, Dong CH. Effects of Songling Xuemaikang Capule on heart rate variability of patients with hypertension. J Clin Electrocardiol (Chin) 2011;5:354–356.

Li H. Clinical observation of Songling Xuemaikang Capsule combined with valsartan in patients with hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2011;9:911–912.

Yin BD. Clinical observation of Songling Xuemaikang Capsule combined with losartan on 76 cases of primary hypertension. Med Inform (Chin) 2011;24:4926–4927.

Cui JJ, Wei L, Peng DL. Efficacy assessment of Songling Xuemaikang Capsule on the quality of life in patients with hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2011;9:533–534.

Wang FQ. The efficacy of Songling Xuemaikang Capsule combined with amlodipine on reduction of blood pressure variability on patients with primary hypertension. Jilin J Tradit Chin Med (Chin) 2011;31:149–150.

Xu LR, Gao XW, Chen JX. Clinical effect of Songling Xuemaikang Capsule on 180 patients in excess liver-yang with elderly hypertension. Fujian J Tradit Chin Med (Chin) 2010;41:45–46.

Li XY, Du YB, Chen WL. Effects of Songling Xuemaikang Capsule on blood pressure and left ventricular hypertrophy in patients with elderly hypertension. Yunnan J Tradit Chin Med Mater Med (Chin) 2009;30:10–12.

Liu J. Clinical observation of Songling Xuemaikang Capsule combined with benazepril in the treatment of non-dipper hypertension. Med J Commun (Chin) 2007;21:648–649.

He ZM, Liang YR. Discussion of valsartan combined with Songling Xuemaikang Capsule on treatment of primary hypertension. Pract J Cardiac Cerebral Pneumal Vasc Dis (Chin) 2006;14:968–969.

Wang Q, Qiao K. The comparison of Songling Xuemaikang Capsule with nifedipine GITS on treatment of primary hypertension. West China J Pharmac Sci (Chin) 2006;21:107–108.

Weng JL, Zhang FW. Clinical observation of Songling Xuemaikang Capsule combined with losartan potassium in patients with excess liver-yang and hypertension. Chin General Pract (Chin) 2005;8:933–935.

Wang F, Kang J. Clinicla observation of Songling Xuemaikang Capsule on primary hypertension. China Naturop (Chin) 2004;12:57–59.

Chen WQ, Chen FR. Effects of Songling Xuemaikang Capsule combined with captopril on the quality of life of patients with primary hypertension. Chin J Integr Tradit West Med (Chin) 2001;21:660–662.

Wang YT, Guo YG. Clinical observation of Songling Xuemaikang Capsule on treatment of hypertension. Strait Pharmac J (Chin) 1997;9:37–38.

Xiong XJ, Yang XC, Liu YM, Zhang Y, Wang PQ, Wang J. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypert Res 2013;36:570–579.

Xiong XJ, Yang XC, Liu W, Chu FY, Wang PQ, Wang J. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complem Altern Med 2013; 1–13, Article ID 275279.

Wang J, Xiong XJ, Zhang YQ, Liu YM, Zhang Y, Zhang ZP, et al. Chinese herbal medicine qi ju di huang wan for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complemt Alternat Med 2013;2013:262685.

Wang JS, Heijden RVD, Spruit S, Hankermeier T, Chan K, Greef JVD, et al. Quality and safety of Chinese herbal medicines guided by a systems biology perspective. J Ethnopharmacol 2009;126:31–41.

Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003;52:1361–1371.

Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, Bauer R. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 1999;282:28–29.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Scalp acupuncture for Parkinson’s disease: A systematic review of randomized controlled trials

Acupuncture Treatment for Post-Stroke Dysphagia: An Update Meta-Analysis of Randomized Controlled Trials

Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials

Ginkgo Leaf Extract and Dipyridamole Injection as Adjuvant Treatment for Angina Pectoris: A Meta-Analysis of 41 Randomized Controlled Trials

Anti-inflammatory effects of Reduning Injection (热毒宁注射液) on lipopolysaccharide-induced acute lung injury of rats